Trusted from concept to supply
See why scientists, from top 10 pharma to small biotech and academic institutions, choose to partner with Aptamer Group, in their own words.
“We had excellent performance of the Optimer® in our assay, which was better than any of the other many antibodies and antibody conditions that we had tried. Even from the first run the Optimer® outperformed the best conditions for the best antibody, straight out of the box. No protocol tweaks, no nothing, just superior out the gate.”
Senior Advisor, Top 10 pharma company
“Over the last month, we’ve been trialling western blots and ELISAs. Having processed all the samples, we have reached a very definite conclusion that Optimers are the optimal target binder, with antibody-based detection struggling to meet the LOQ and proving non-specific.”
Senior Scientist, Diagnostic company
“Aptamer Group is our preferred aptamer supplier. Their platform recognises the additional needs of cell scientists and, importantly, delivers quickly.”
Technical Innovation Scientist, Top 20 pharma company
“Working with Aptamer Group has opened up new avenues for our technology, highlighting its compatibility beyond standard antibodies to work with the next generation of targeting ligands, like Optimer® binders. The team at Aptamer brings the same innovative scientific approach with a commercial mindset that we embrace, allowing us to work at pace to provide novel solutions that could improve treatment for cancer patients globally.”
Chief Executive Officer, Clinical-stage oncology biotech
“From the initial conversations to the final presentation and technical results, the entire team met or exceeded all expectations.”
Senior Researcher, Top 10 pharma company
“We had previously tried an alternative aptamer company, and the results were not sensitive or specific enough. The innovative solutions we developed with Aptamer Group are showing excellent results and could revolutionise early diagnosis within our field.”
Chief Scientific Officer, Women’s health biotech company
“The team at Aptamer Group has been hugely supportive in developing methods and sharing tips and techniques. We are at the cutting edge of research, so many of these techniques and targets are very new.”
Research Fellow, Russell Group University
“We recognise Aptamer Group for the quality of their delivery and advanced support with assay integration.”
Chief Scientific Officer, Wearable biotech company
Pushing for a new paradigm in disease management
Dr Netz Arroyo from Johns Hopkins University School of Medicine is developing aptamer-based point-of-care assays and wearable sensors for improved disease management
Hitting a therapeutic sweet spot with Optimer®
Dr Daniel Wiseman from the
Christie NHS Foundation is investigating Optimer® as a novel therapeutic strategy for treating leukemia, with advantages over other modalities.